KR20140108520A - CD1d에 대한 항체 - Google Patents

CD1d에 대한 항체 Download PDF

Info

Publication number
KR20140108520A
KR20140108520A KR1020147012848A KR20147012848A KR20140108520A KR 20140108520 A KR20140108520 A KR 20140108520A KR 1020147012848 A KR1020147012848 A KR 1020147012848A KR 20147012848 A KR20147012848 A KR 20147012848A KR 20140108520 A KR20140108520 A KR 20140108520A
Authority
KR
South Korea
Prior art keywords
seq
cd1d
ser
gly
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020147012848A
Other languages
English (en)
Korean (ko)
Inventor
조나단 칸난 남비아르
린 도로시 폴톤
아담 클라크
앤드류 제임스 포우
데브라 탐바키스
조지 캅시다스
안소니 제라드 도일
매튜 폴라드
휘세인 무스타파
Original Assignee
테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2011904190A external-priority patent/AU2011904190A0/en
Application filed by 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 filed Critical 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디
Publication of KR20140108520A publication Critical patent/KR20140108520A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020147012848A 2011-10-14 2012-10-15 CD1d에 대한 항체 Withdrawn KR20140108520A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161547307P 2011-10-14 2011-10-14
US61/547,307 2011-10-14
AU2011904190 2011-10-14
AU2011904190A AU2011904190A0 (en) 2011-10-14 Antibodies to CD1d
PCT/AU2012/001247 WO2013053021A1 (en) 2011-10-14 2012-10-15 ANTIBODIES TO CD1d

Publications (1)

Publication Number Publication Date
KR20140108520A true KR20140108520A (ko) 2014-09-11

Family

ID=48081279

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147012848A Withdrawn KR20140108520A (ko) 2011-10-14 2012-10-15 CD1d에 대한 항체

Country Status (14)

Country Link
US (1) US20140286957A1 (https=)
EP (1) EP2766042A4 (https=)
JP (1) JP2015502915A (https=)
KR (1) KR20140108520A (https=)
CN (1) CN104144700B (https=)
AU (1) AU2012323781B8 (https=)
BR (1) BR112014008691A2 (https=)
CA (1) CA2850961A1 (https=)
EA (1) EA201400447A1 (https=)
IL (1) IL231975A0 (https=)
MX (1) MX2014004326A (https=)
SG (1) SG11201400521PA (https=)
WO (1) WO2013053021A1 (https=)
ZA (1) ZA201401776B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10501541B2 (en) 2015-01-27 2019-12-10 Lava Therapeutics B.V. Single domain antibodies targeting CD1d
DK3440106T3 (da) * 2016-04-08 2021-10-04 Adaptimmune Ltd T-cellereceptorer
SMT202200306T1 (it) * 2016-04-08 2022-09-14 Immunocore Ltd Recettori di cellule t
BR112018070637A2 (pt) * 2016-04-08 2019-02-05 Adaptimmune Ltd receptores de células t
CN108079292A (zh) * 2016-11-23 2018-05-29 苏州盛迪亚生物医药有限公司 一种抗pd-1抗体在制备治疗肝癌的药物中的用途
EP4417210A1 (en) * 2017-03-15 2024-08-21 Orca Biosystems, Inc. Compositions and methods for hematopoietic stem cell transplants
AU2019344300A1 (en) 2018-09-19 2021-04-22 LAVA Therapeutics N.V. Dual acting CD1D immunoglobulin
GB201820006D0 (en) * 2018-12-07 2019-01-23 Lifearc Humanised anti-IL17BR antibody
SMT202500106T1 (it) * 2020-08-18 2025-05-12 Cephalon Llc Anticorpi anti-par-2 e loro metodi d'uso
KR20230126714A (ko) * 2020-12-18 2023-08-30 바이오아르디스 엘엘씨 메소텔린 결합 분자 및 이의 사용
KR20250070621A (ko) 2022-08-18 2025-05-20 이뮤노코어 리미티드 Mage-a4에 특이적인 t 세포 수용체 융합 단백질
CN116217704B (zh) * 2022-10-25 2025-08-15 南京医科大学 一种抑制肝细胞凋亡的表面分子及其应用
KR20250128342A (ko) * 2022-12-21 2025-08-27 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 입양 면역요법을 위한 향상된 기능을 갖는 cd3 및 itcr을 발현하는 조작된 자연살해세포
WO2024226794A1 (en) * 2023-04-26 2024-10-31 The Trustees Of Indiana University Composition and methods for treatment of spinal cord injury and traumatic brain injury

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1095062B1 (en) * 1998-07-09 2006-09-13 Brian J. Nickoloff Method of treating disorders by modulating the interaction of natural killer receptors on t cells with their respective ligands
US8084020B2 (en) * 2002-05-01 2011-12-27 Beth Israel Deaconess Medical Center Use of anti-CD1 antibodies for the modulation of immune responses
WO2008100912A1 (en) * 2007-02-12 2008-08-21 The General Hospital Corporation Methods for attenuating allergen-induced airway hyperreactivity using cd1d dependent antagonists
US8012484B2 (en) * 2007-04-12 2011-09-06 University Of Virginia Patent Foundation Method of treating ischemia reperfusion injury by inhibiting NKT cell activity

Also Published As

Publication number Publication date
ZA201401776B (en) 2016-01-27
NZ622050A (en) 2016-07-29
CN104144700A (zh) 2014-11-12
AU2012323781B2 (en) 2015-04-23
SG11201400521PA (en) 2014-08-28
JP2015502915A (ja) 2015-01-29
AU2012323781A1 (en) 2014-03-27
CN104144700B (zh) 2016-10-19
CA2850961A1 (en) 2013-04-18
AU2012323781B8 (en) 2015-05-14
BR112014008691A2 (pt) 2017-06-13
AU2012323781A8 (en) 2015-05-14
WO2013053021A1 (en) 2013-04-18
IL231975A0 (en) 2014-05-28
EP2766042A1 (en) 2014-08-20
MX2014004326A (es) 2014-09-25
EA201400447A1 (ru) 2014-09-30
EP2766042A4 (en) 2015-05-27
US20140286957A1 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
KR20140108520A (ko) CD1d에 대한 항체
US20210347904A1 (en) Antibodies against tl1a and uses thereof
CN102782148B (zh) 与多种cc趋化因子结合的抗因子抗体
AU2010270241B2 (en) Humanised antibodies to Toll-like Receptor 2 and uses thereof
CN102300997B (zh) Toll样受体3拮抗剂
US20210355196A1 (en) Sars-cov-2 antibodies and methods of selecting and using the same
TWI797124B (zh) 抗干擾素-γ之抗體及其應用
EP3632932A1 (en) Anti-cd40 antibody, antigen binding fragment thereof and medical use thereof
JP2018118970A (ja) 代謝性疾患及び心臓血管疾患を治療するためのｔｏｌｌ様受容体３アンタゴニスト
TW202003570A (zh) 抗trem-1抗體及其用途
KR20230078657A (ko) 자가면역 질환 및 암을 치료하기 위한 방법 및 조성물
TW202229337A (zh) 犬抗體變異體
WO2020221451A1 (en) Antibodies binding to plasmodium circumsporozoite protein and uses thereof
WO2013039471A1 (en) Toll-like receptor 3 antagonists for the treatment of metabolic and cardiovascular diseases
JP2025541734A (ja) Ｂｔｌａアゴニスト抗体及びその使用
TW202336035A (zh) 治療自體免疫疾病及癌症之方法及組成物
JP2025524927A (ja) カンナビノイド受容体１型結合タンパク質及びその使用
WO2024068996A1 (en) Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
NZ622050B2 (en) ANTIBODIES TO CD1d
EA046142B1 (ru) Антитела к trem-1 и их применения

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140513

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid